Prof. Dr. Ambros J. Beer

Ärztlicher Direktor (*1972)

Klinik für Nuklearmedizin, Universität Ulm
Albert-Einstein-Allee 23, 89081 Ulm, Deutschland

Telefon: 0731 500-61300
Fax: 0731 500-61302

E-Mail: info.nuklearmedizin@uniklinik-ulm.de

 

Molekulare Bildgebung, Hybridbildgebung inkl. PET/MR und PET/CT, imaging of angiogenesis

1992-1999

Studium der Medizin: Ludwig-Maximilians-Universität München

1999

Promotion, Institut für Strahlenbiologie, Ludwig-Maximilians-Universität München (Prof. Dr. E. Lengfelder)

2001

Approbation

1999-2001

Assistenzarzt, Institut für diagnostische und interventionelle Radiologie der Technischen Universität München (TUM), Klinikum rechts der Isar

2001

Consultant, Siemens Medical Solutions, CT Concepts

2001-2003

Assistenzarzt, Institut für diagnostische und interventionelle Radiologie TUM, Klinikum rechts der Isar

2003-2004

Assistenzarzt, Klinik für Nuklearmedizin TUM, Klinikum rechts der Isar

2004-2006

Assistenzarzt, Institut für diagnostische und interventionelle Radiologie, Klinikum rechts der Isar

2006-2009

Assistenzarzt, Klinik für Nuklearmedizin TUM, Klinikum rechts der Isar

2006

Facharztprüfung Radiologie

2007

Habilitation Nuklearmedizin

2009

Facharztprüfung Nuklearmedizin

2009-2014

Oberarzt, Klinik für Nuklearmedizin TUM, Klinikum rechts der Isar

2014

“apl. Professor” für Nuklearmedizin

seit 2014

Professur und Ärztlicher Direktor der Klinik für Nuklearmedizin, Universität Ulm

  • “Image of the year”, Jahrestagung der DGN 2004, Rostock
  • “Young Investigator Award for the Year 2005“ der „Society for the Advancement of Nuclear Medicine at the Technische Universität München”
  • 2005 First Place Award “Outstanding Clinical Investigations” des Journal of Nuclear Medicine. Jahrestagung SNM 2006, San Diego
  • 2007 bestes klinisches Paper (3. Platz) des Young Professionals Committee der Society for Nuclear Medicine. Jahrestagung SNM 2007, Washington
  • Bestplatzierung “Cardiovascular sciences young investigator award symposium” Jahrestagung SNM 2008, New Orleans
  • Ehrenpreis 2008 der Bayerischen Röntgengesellschaft: “Visualization of antigen-specific human cytotoxic T lymphocytes labeled with superparamagnetic iron-oxide particles”
  • Ehrenpreis 2008 der Bayerischen Röntgengesellschaft: “Magnetic Resonance Imaging in Patients with Rectal Cancer before Neoadjuvant Chemoradiotherapy for Prediction of Tumor-Free Circumferential Resection Margins and Long-Term Survival”
  • Molecular Imaging Travel Award der RSNA für die Veröffentlichung "PET-MRI Correlation of Diffusion-weighted MR Imaging and 11C-Choline PET/CT for Characterization of Pelvic Lymph Node Metastases in Patients with Prostate Cancer"; Jahrestagung RSNA 2009, Chicago
  • Molecular Imaging Center of Excellence Young investigator award (2. Platz). Jahrestagung SNM 2010, Salt Lake City
  • Deutsche Gesellschaft für Nuklearmedizin (DGN)
  • European Association of Nuclear Medicine (EANM)
  • Deutsche Röntgengesellschaft
  • Society of Nuclear Medicine (SNM)
  • Radiological Society of North America (RSNA)
  • International Advisory Board “The Lancet Oncology”
  • EJNMMI Research
  • Wissenschaftlicher Beirat „Der Nuklearmediziner“
  • Tomography
  • European Radiology (2010-2016)
  • The Open Medical Imaging Journal
  • Mitglied des Ausschusses „Clinical Quality Management“ der DGN

  • EORTC Protocol Review Ausschuss

  • SNMMI PET/MRI Task Force

Gutachter für wissenschaftliche Organisationen

 

  • Cancer Research UK

  • Deutsche Forschungsgemeinschaft DFG

  • Deutsche Krebshilfe

  • FWF Fonds zur Förderung der wissenschaftlichen Forschung (Österreich)

  • Manchester Cancer Research Centre MCRC

  • Medical Research Council MRC

  • Medizinische Universität Wien

  • Ministère de l’Enseignement supérieur et de la Recherche (Französisches Ministerium für Bildung und Forschung)

  • Pancreatic Cancer UK PCUK

  • Swiss National Science Foundation SNSF

  • Wilhelm Sander-Stiftung

 

Bei Kongressen

  • World Molecular Imaging Conference WMIC

  • Jahrestagung der Society of Nuclear Medicine and Molecular Imaging SNMMI

  • European Congress of Radiology

  • Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin DGN

für wissenschaftliche Journale

Academic Radiology, American Journal of Respiratory and Critical Care Medicine, American Journal of Roentgenology AJR, AJR Integrative Imaging, Amino Acids, Angiogenesis Reviews, Annals of Nuclear Medicine, Bioconjugate Chemistry, BMC Cancer, British Journal of Cancer, Cancer Imaging, Cancer Letters, Cancer Research, Circulation, Clinical Cancer Research, Computers in Biology and Medicine, Current Nanoscience, Current Pharmaceutical Design, European Journal of Hematology, European Journal of Nuclear Medicine and Molecular Imaging, European Journal of Nuclear Medicine and Molecular Imaging Research, European Radiology, Expert Review of Medical Devices, Expert Review of Anticancer Therapy, Imaging in Medicine, International Journal of Cancer, Investigative Radiology, Journal of Clinical Endocrinology & Metabolism, Journal of Magnetic Resonance Imaging, Journal of Nuclear Medicine, Journal of Postgraduate Medicine, Journal of Surgical Oncology, Lancet Oncology, Lung Cancer International, Medicinal Research Reviews, Molecular Imaging, Molecular Imaging and Biology, Molecular Pharmaceutics, Nature Reviews Oncology, Nuclear Medicine and Biology, Nuclear Medicine Communications, Nuklearmedizin, Oncotarget, PLoS One, Radiologe, Theranostics, World Journal of Radiology, Yonsei Medical Journal

  • Lisson CS, Lisson CG, Flosdorf K, Mayer-Steinacker R, Schultheiss M, von Baer A, Barth TFE, Beer AJ, Baumhauer M, Meier R, Beer M, Schmidt SA. Diagnostic value of MRI-based 3D texture analysis for tissue characterisation and discrimination of low-grade chondrosarcoma from enchondroma: a pilot study. Eur Radiol. 2017 Sep 7. [Epub ahead of print]

  • Eiber M, Rauscher I, Souvatzoglou M, Maurer T, Schwaiger M, Holzapfel K, Beer AJ. Prospective head-to-head comparison of 11C-choline-PET/MR and 11C-choline-PET/CT for restaging of biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2017 Aug 12. [Epub ahead of print]

  • Kramer L, Winter G, Baur B, Kuntz AJ, Kull T, Solbach C, Beer AJ, Lindén M. Quantitative and correlative biodistribution analysis of 89Zr-labeled mesoporous silica nanoparticles intravenously injected into tumor-bearing mice. Nanoscale. 2017 Jul 13;9(27):9743-9753.

  • Weber T, Gottstein M, Schwenzer S, Beer A, Luster M. Is C-11 Methionine PET/CT Able to Localise Sestamibi-Negative Parathyroid Adenomas? World J Surg. 2017 Apr;41(4):980-985.

  • Beer AJ, Dijkgraaf I. Editorial European Journal of Nuclear Medicine and Molecular Imaging. Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):284-285.

  • O'Connor JP, Aboagye EO, Adams JE, Aerts HJ, Barrington SF, Beer AJ, Boellaard R, Bohndiek SE, Brady M, Brown G, Buckley DL, Chenevert TL, Clarke LP, Collette S, Cook GJ, deSouza NM, Dickson JC, Dive C, Evelhoch JL, Faivre-Finn C, Gallagher FA, Gilbert FJ, Gillies RJ, Goh V, Griffiths JR, Groves AM, Halligan S, Harris AL, Hawkes DJ, Hoekstra OS, Huang EP, Hutton BF, Jackson EF, Jayson GC, Jones A, Koh DM, Lacombe D, Lambin P, Lassau N, Leach MO, Lee TY, Leen EL, Lewis JS, Liu Y, Lythgoe MF, Manoharan P, Maxwell RJ, Miles KA, Morgan B, Morris S, Ng T, Padhani AR, Parker GJ, Partridge M, Pathak AP, Peet AC, Punwani S, Reynolds AR, Robinson SP, Shankar LK, Sharma RA, Soloviev D, Stroobants S, Sullivan DC, Taylor SA, Tofts PS, Tozer GM, van Herk M, Walker-Samuel S, Wason J, Williams KJ, Workman P, Yankeelov TE, Brindle KM, McShane LM, Jackson A, Waterton JC. Imaging biomarker roadmap for cancer studies. Nat Rev Clin Oncol. 2017 Mar;14(3):169-186.

  • Rauscher I, Maurer T, Beer AJ, Graner FP, Haller B, Weirich G, Doherty A, Gschwend JE, Schwaiger M, Eiber M. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy. J Nucl Med. 2016 Nov;57(11):1713-1719.

  • Kletting P, Schuchardt C, Kulkarni HR, Shahinfar M, Singh A, Glatting G, Baum RP, Beer AJ. Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for 177Lu-Labeled PSMA-Targeting Peptides. PLoS One. 2016 Sep 9;11(9):e0162303.

  • Leuzy A, Chiotis K, Hasselbalch SG, Rinne JO, de Mendonça A, Otto M, Lleó A, Castelo-Branco M, Santana I, Johansson J, Anderl-Straub S, von Arnim CA, Beer A, Blesa R, Fortea J, Herukka SK, Portelius E, Pannee J, Zetterberg H, Blennow K, Nordberg A. Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study. Brain. 2016 Sep;139(Pt 9):2540-53.

  • Rauscher I, Maurer T, Souvatzoglou M, Beer AJ, Vag T, Wirtz M, Weirich G, Wester HJ, Gschwend JE, Schwaiger M, Schottelius M, Eiber M. Intrapatient Comparison of 111In-PSMA I&T SPECT/CT and Hybrid 68Ga-HBED-CC PSMA PET in Patients With Early Recurrent Prostate Cancer. Clin Nucl Med. 2016 Sep;41(9):e397-402.

  • Beer AJ, Schwarzenböck SM, Zantl N, Souvatzoglou M, Maurer T, Watzlowik P, Kessler H, Wester HJ, Schwaiger M, Krause BJ. Non-invasive assessment of inter-and intrapatient variability of integrin expression in metastasized prostate cancer by PET. Oncotarget. 2016 May 10;7(19):28151-9.

  • Taouli B, Beer AJ, Chenevert T, Collins D, Lehman C, Matos C, Padhani AR, Rosenkrantz AB, Shukla-Dave A, Sigmund E, Tanenbaum L, Thoeny H, Thomassin-Naggara I, Barbieri S, Corcuera-Solano I, Orton M, Partridge SC, Koh DM. Diffusion-weighted imaging outside the brain: Consensus statement from an ISMRM-sponsored workshop. J Magn Reson Imaging. 2016 Sep;44(3):521-40.

  • Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, Beer AJ, Wester HJ, Gschwend J, Schwaiger M, Maurer T. Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. Eur Urol. 2016 Nov;70(5):829-836.

  • Crönlein M, Rauscher I, Beer AJ, Schwaiger M, Schäffeler C, Beirer M, Huber S, Sandmann GH, Biberthaler P, Eiber M, Kirchhoff C. Visualization of stress fractures of the foot using PET-MRI: a feasibility study. Eur J Med Res. 2015 Dec 23;20:99.

  • Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, Wester HJ, Heck M, Kübler H, Beer AJ, Schwaiger M, Eiber M. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. J Urol. 2016 May;195(5):1436-43.

  • Kletting P, Kull T, Maaß C, Malik N, Luster M, Beer AJ, Glatting G. Optimized Peptide Amount and Activity for ⁹⁰Y-Labeled DOTATATE Therapy. J Nucl Med. 2016 Apr;57(4):503-8.

  • D'Alessandria C, Pohle K, Rechenmacher F, Neubauer S, Notni J, Wester HJ, Schwaiger M, Kessler H, Beer AJ. In vivo biokinetic and metabolic characterization of the 68Ga-labelled α5β1-selective peptidomimetic FR366. Eur J Nucl Med Mol Imaging. 2015 Oct 24

  • Metz S, Ganter C, Lorenzen S, van Marwick S, Holzapfel K, Herrmann K, Rummeny EJ, Wester HJ, Schwaiger M, Nekolla SG, Beer AJ. Multiparametric MR and PET Imaging of Intratumoral Biological Heterogeneity in Patients with Metastatic Lung Cancer Using Voxel-by-Voxel Analysis. PLoS One. 2015 Jul 17;10(7):

  • Meier R, Braren R, Kosanke Y, Bussemer J, Neff F, Wildgruber M, Schwarzenböck S, Frank A, Haller B, Hohlbaum AM, Schwaiger M, Gille H, Rummeny EJ, Beer AJ. Multimodality multiparametric imaging of early tumor response to a novel antiangiogenic therapy based on anticalins. PLoS One. 2014 May 6;9(5

  • Trajkovic-Arsic M, Mohajerani P, Sarantopoulos A, Kalideris E, Steiger K, Esposito I, Ma X, Themelis G, Burton N, Michalski CW, Kleeff J, Stangl S, Beer AJ, Pohle K, Wester HJ, Schmid RM, Braren R, Ntziachristos V, Siveke JT. Multimodal molecular imaging of integrin αvβ3 for in vivo detection of pancreatic cancer. J Nucl Med. 2014 Mar;55(3):446-51

  • Beer AJ, Pelisek J, Heider P, Saraste A, Reeps C, Metz S, Seidl S, Kessler H, Wester HJ, Eckstein HH, Schwaiger M.PET/CT imaging of integrin αvβ3 expression in human carotid atherosclerosis. JACC Cardiovasc Imaging. 2014 Feb;7(2):178-87

  • Eiber M, Takei T, Souvatzoglou M, Mayerhoefer ME, Fürst S, Gaertner FC, Loeffelbein DJ, Rummeny EJ, Ziegler SI, Schwaiger M, Beer AJ. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions. J Nucl Med. 2014 Feb;55(2):191-7

  • Neubauer S, Rechenmacher F, Beer AJ, Curnis F, Pohle K, D'Alessandria C, Wester HJ, Reuning U, Corti A, Schwaiger M, Kessler H. Selective imaging of the angiogenic relevant integrins α5β1 and αvβ3. Angew Chem Int Ed Engl. 2013 Oct 25;52(44):11656-9

  • Martinez-Möller A, Eiber M, Nekolla SG, Souvatzoglou M, Drzezga A, Ziegler S, Rummeny EJ, Schwaiger M, Beer AJ. Workflow and scan protocol considerations for integrated whole-body PET/MRI in oncology. J Nucl Med. 2012 Sep;53(9):1415-26

  • Beer AJ, Eiber M, Souvatzoglou M, Schwaiger M, Krause BJ. Radionuclide and hybrid imaging of recurrent prostate cancer. Lancet Oncol. 2011 Feb;12(2):181-91

  • Beer AJ, Grosu AL, Carlsen J, Kolk A, Sarbia M, Stangier I, Watzlowik P, Wester HJ, Haubner R, Schwaiger M. [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6610-6